Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer

Value in Health

Volumn 10, Issue 5, 2007, Pages 367-376

  Thompson, David ^a   Taylor, Douglas C A ^a   Montoya, Eduardo L ^a   Winer, Eric P ^c   Jones, Stephen E ^d   Weinstein, Milton C ^a,b  

^a i3 Global   (Canada)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

Breast cancer; Cost effectiveness; Decision analysis; Hormonal therapy

Indexed keywords

EXEMESTANE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; ENDOMETRIUM CANCER; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; LIFE EXPECTANCY; MEDICAL CARE; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL;

EID: 34748852542     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00190.x     Document Type: Article

References (35)

1. Food and Drug Administration (FDA). List of Approved Oncology Drugs with Approved Indications. 2005. Available from: http://www.fda.gov/ [Accessed August 2005].
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998 351 : 1451 67.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005 365 : 1687 717.
4. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005 365 : 60 2.
5. Thurlimann BJ, Keshaviah A, Mouridsen H, et al. BIG 1-98: randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. J Clin Oncol (Meeting Abstracts) 2005 23 : 511.
6. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004 350 : 1081 92.
7. Jakesz R, Jonat W, Gnant M, et al., ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005 366 : 455 62.
8. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003 349 : 1793 802.
9. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993 13 : 322 38.
10. Swerdlow AJ, Jones ME for the British Tamoxifen Second Cancer Study Group. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 2005 97 : 375 84.
11. National Cancer Institute. Health Services & Economics - About the SEER-Medicare Database. Available from: http://healthservices.cancer.gov/ seermedicare/overview [Accessed August 2005].
12. Earle CC, Nattinger AB, Potosky AL, et al. Identifying cancer relapse using SEER-Medicare data. Med Care 2002 40 : IV75 81.
13. National Center for Health Statistics. United States Life Tables, National Vital Statistic Report. 2000. Available from: http://www.cdc.gov/nchs/ products/pubs/pubd/nvsr/51/51_03.htm [Accessed August 2005].
14. Fleming T, Lagow B, Murray L, et al. Red Book: Pharmacy's Fundamental Reference (2004 ed.) Montvale, NJ : Thomson PDR, 2004.
15. Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-Medicare data. Value Health (in press).
16. Barnes MN, Roland PY, Straughn M, et al. A comparison of treatment strategies for endometrial adenocarcinoma: analysis of financial impact. Gynecol Oncol 1999 74 : 443 7.
17. Orsini LS, Rousculp MD, Long SR, et al. Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures. Osteoporos Int 2005 16 : 359 71.
18. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York : Oxford University Press, 1996.
19. Hanmer J, Lawrence WF, Anderson JP, et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 2006 26 : 391 400.
20. Sorensen SV, Brown R, Benedict A, Flood E, Revicki D. Patient-rated utilities in postmenopausal early breast cancer (EBC): a cross-country comparison. Value Health 2004 7 : 641 (abstract).
21. Delea TE, Karnon J, Smith RE, et al. Cost-effectiveness of extended adjuvant letrozole therapy after five years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care 2006 12 : 374 86.
22. Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 2000 15 : 1384 92.
23. Armstrong K, Chen TM, Albert D, et al. Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet Gynecol 2001 98 : 996 1003.
24. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York : Chapman & Hall, 1993.
25. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004. J Clin Oncol 2005 25 : 619 29.
26. Schouseboe JT, Nyman JA, Kane RL, et al. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005 142 : 734 41.
27. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000 18 : 3302 17.
28. U.S. Bureau of Labor Statistics. Consumer Price Index - All Urban Consumers: Medical Care (Series CUUR0000SAM). 2005. Available from: http://bls.gov [Accessed August 2005].
29. Elkin EB, Weinstein MC, Winer EP, et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2004 22 : 854 63.
30. Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer 2004 101 : 439 49.
31. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005 23 : 619 29.
32. Lønning PE. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol 2006 17 : 217 25.
33. Hillner BE. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 2004 101 : 1311 22.
34. Locker GY, ATAC Trialists' Group. Cost-utility analysis of anastrozole versus tamoxifen as primary adjuvant therapy in postmenopausal women with early breast cancer, from a US healthcare system perspective: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in Combination) trial. San Antonio Breast Cancer Symposium 2004 (abstract).
35. Punglia RS, Kuntz KM, Winer EP, et al. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 2005 23 : 5178 87.